← Back to Search

Platelet Rich Plasma

PRP for Frontal Fibrosing Alopecia

Waitlist Available
Led By Maria Hordinsky, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Willing to abstain from over the counter and prescription hair/scalp products other than those supplied in the study
Scalp biopsy consistent with frontal fibrosing alopecia diagnosis
Must not have
Current immunosuppression
Current chemotherapy or radiation
Screening 3 weeks
Treatment Varies
Follow Up baseline to 3 years
Awards & highlights


This trial will assess whether platelet rich plasma can help treat symptoms and promote hair growth in patients with frontal fibrosing alopecia.

Who is the study for?
This trial is for adults with frontal fibrosing alopecia, who can consent and follow the study rules. They must not be pregnant or breastfeeding, avoid certain medications and supplements, use specific shampoo, and agree to contraception if applicable. People with scalp atrophy, severe allergies, bleeding disorders or on certain treatments are excluded.Check my eligibility
What is being tested?
The trial tests platelet rich plasma (PRP) prepared using Eclipse Easy Spin centrifuge for treating frontal fibrosing alopecia. PRP will be injected into the affected scalp area to see if it reduces symptoms and promotes hair growth.See study design
What are the potential side effects?
Potential side effects may include discomfort at injection sites, risk of infection from injections, possible allergic reactions to materials used in PRP preparation or triamcinolone allergy/intolerance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am willing to only use the hair/scalp products provided by the study.
My scalp biopsy confirmed I have frontal fibrosing alopecia.
I am able to understand and agree to the study's procedures and risks.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I am currently on medication that weakens my immune system.
I am currently undergoing chemotherapy or radiation.
I currently have cancer.
I have taken medication like hydroxychloroquine or prednisone in the last 3 months.
I have a problem with how my blood clots.
I have HIV, a connective tissue disorder, PCOS, or untreated thyroid disease.
My scalp is thinning.
I have a blood or bleeding disorder.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in the LPPAI score from baseline
Changes in the hair growth from baseline to the completion of the study • Change in hair growth from baseline to study completion via investigator assessment of scalp photography
Secondary outcome measures
self-assessment using the Dermatology Quality Life Index

Trial Design

1Treatment groups
Experimental Treatment
Group I: Eclipse Easy Spin for PRP TreatmentExperimental Treatment1 Intervention
Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Frontal Fibrosing Alopecia (FFA) treatments, such as Platelet Rich Plasma (PRP), work by releasing growth factors that stimulate tissue repair and hair follicle regeneration. This is important for FFA patients because the condition involves inflammation and scarring that lead to hair loss. By promoting tissue repair and reducing inflammation, PRP and similar treatments can potentially restore hair growth and improve scalp health. Other treatments, like corticosteroids and immunosuppressants, reduce inflammation and modulate the immune response, addressing the autoimmune component of FFA.
Autologous activated platelet-rich plasma in hair growth: A pilot study in male androgenetic alopecia with in vitro bioactivity investigation.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,395 Previous Clinical Trials
1,553,305 Total Patients Enrolled
1 Trials studying Frontal Fibrosing Alopecia
5 Patients Enrolled for Frontal Fibrosing Alopecia
Maria Hordinsky, MDPrincipal InvestigatorUniversity of Minnesota Department of Dermatology
16 Previous Clinical Trials
438 Total Patients Enrolled
Ronda Farah, MDPrincipal InvestigatorUniversity of Minnesota Department of Dermatology
2 Previous Clinical Trials
80 Total Patients Enrolled

Media Library

Platelet Rich Plasma (Platelet Rich Plasma) Clinical Trial Eligibility Overview. Trial Name: NCT03335228 — N/A
Frontal Fibrosing Alopecia Research Study Groups: Eclipse Easy Spin for PRP Treatment
Frontal Fibrosing Alopecia Clinical Trial 2023: Platelet Rich Plasma Highlights & Side Effects. Trial Name: NCT03335228 — N/A
Platelet Rich Plasma (Platelet Rich Plasma) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03335228 — N/A
~13 spots leftby Sep 2025